Catalyst Event

Moderna Inc (MRNA) · Other

From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)

6/8/2026, 12:00:00 AM

OtherSentiment: Positive

On June 8, 2026, Moderna and the University of Oxford announced they received authorization from the UK's MHRA to begin a Phase 1/2 clinical trial for mRNA-4194, an investigational preventive cancer vaccine for people with Lynch Syndrome. Early-stage trial starts typically have a low price impact (1-5%), expected.

Korean Translation

2026년 6월 8일 발표된 린치 증후군 암 백신 1/2상 임상 승인이 1-5% 수준의 제한적인 주가 영향을 미칠 것으로 예상됨.

Related Recent Events

View Full Timeline